Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 202-210

  Arribillaga, Laura ^a   De Cerio, Ascensión López Díaz ^a,b   Sarobe, Pablo ^a   Casares, Noelia ^a   Gorraiz, Marta ^a   Vales, Africa ^a   Bruna Romero, Oscar ^a   Borrás Cuesta, Francisco ^a   Paranhos Baccala, Glaucia ^b   Prieto, Jesús ^a   Ruiz, Juan ^a   Lasarte, Juan José ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b BIOMÉRIEUX   (France)

Author keywords

Hepatitis C virus; In vivo protection; Recombinant adenovirus

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; NONSTRUCTURAL PROTEIN 3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMORAL IMMUNITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VACCINIA VIRUS; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALS; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0037073569     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00456-5     Document Type: Article

References (53)

1. World Health Organisation. Hepatitis C. Wkly Epidemiol Rec 1997;72:65.
2. Dienstag J.L. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology. 85(2):1983;439-462.
3. Camps J., Castilla A., Ruiz J., Civeira M.P., Prieto J. Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J. Hepatol. 17(3):1993;390-396.
4. Poynard T., Marcellin P., Lee S.S.et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 352(9138):1998;1426-1432.
5. Rosa D., Campagnoli S., Moretto C.et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc. Natl. Acad. Sci. U.S.A. 93(5):1996;1759-1763.
6. Botarelli P., Brunetto M.R., Minutello M.A.et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology. 104(2):1993;580-587.
7. Ferrari C., Valli A., Galati L.et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology. 19(2):1994;286-295.
8. Missale G., Bertoni R., Lamonaca V.et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98(3):1996;706-714.
9. Takaki A., Wiese M., Maertens G.et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6(5):2000;578-582.
10. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology. 21(3):1995;632-638.
11. Sarobe P., Jauregui J.I., Lasarte J.J.et al. Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. J. Hepatol. 25(1):1996;1-9.
12. Lasarte J.J., Garcia Granero M., Lopez A.et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 28(3):1998;815-822.
13. Lechmann M., Ihlenfeldt H.G., Braunschweiger I.et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology. 24(4):1996;790-795.
14. Diepolder H.M., Zachoval R., Hoffmann R.M.et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 346(8981):1995;1006-1007.
15. Nelson D.R., Marousis C.G., Ohno T., Davis G.L., Lau J.Y.et al. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology. 28(1):1998;225-230.
16. Lohr H.F., Schmitz D., Arenz M.et al. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J. Hepatol. 31(3):1999;407-415.
17. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. U.S.A. 96(10):1999;5692-5697.
18. Cooper S., Erickson A.L., Adams E.J.et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 10(4):1999;439-449.
19. + T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 181(5):2000;1528-1536.
20. Thimme R., Oldach D., Chang K.M.et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194(10):2001;1395-1406.
21. Vertuani S., Bazzaro M., Gualandi G.et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 32(1):2002;144-154.
22. Wilkinson G.W., Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 20(9):1992;2233-2239.
23. Cheynet V., Verrier B., Mallet F. Overexpression of HIV-1 proteins in Escherichia coli by a modified expression vector and their one-step purification. Protein Expr. Purif. 4(5):1993;367-372.
24. McGrory W.J., Bautista D.S., Graham F.L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 163(2):1988;614-617.
25. Bruna-Romero O., Lasarte J.J., Wilkinson G.et al. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology. 25(2):1997;470-477.
26. Borras Cuesta F., Golvano J., Sarobe P.et al. Insights on the amino acid side-chain interactions of a synthetic T-cell determinant. Biologicals. 19(3):1991;187-190.
27. Rammensee H.G., Falk K., Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11:1993;213-244.
28. d exploits a four residue peptide binding motif. J. Exp. Med. 178(6):1993;1877-1892.
29. d: sequence motif, quantitative binding, and molecular modeling of the complex. J. Exp. Med. 176(6):1992;1681-1692.
30. Lasarte J.J., Sarobe P., Gullon A., Prieto J., Borras Cuesta F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell Immunol. 141(1):1992;211-218.
31. Lai M.Z., Ross D.T., Guillet J.G.et al. T lymphocyte response to bacteriophage lambda repressor cI protein. Recognition of the same peptide presented by Ia molecules of different haplotypes. J. Immunol. 139(12):1987;3973-3980.
32. + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102(12):1998;2072-2081.
33. Pape G.R., Gerlach T.J., Diepolder H.M.et al. Role of the specific T-cell response for clearance and control of hepatitis C virus. J. Viral Hepatol. 6(Suppl. 1):1999;36-40.
34. Cerny A., McHutchison J.G., Pasquinelli C.et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 95(2):1995;521-530.
35. Kurokohchi K., Akatsuka T., Pendleton C.D.et al. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J. Virol. 70(1):1996;232-240.
36. Jacobs S.C., Stephenson J.R., Wilkinson G.W. Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. J. Gen. Virol. 75(Part 9):1994;2399-2402.
37. Del Val M., Schlicht H.J., Volkmer H.et al. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J. Virol. 65(7):1991;3641-3646.
38. Klavinskis L.S., Whitton J.L., Oldstone M.B. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J. Virol. 63(10):1989;4311-4316.
39. Fooks A.R., Schadeck E., Liebert U.G.et al. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology. 210(2):1995;456-465.
40. Gallichan W.S., Johnson D.C., Graham F.L., Rosenthal K.L. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis. 168(3):1993;622-629.
41. Stittelaar K.J., Wyatt L.S., de Swart R.L.et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74(9):2000;4236-4243.
42. Shiver J.W., Fu T.M., Chen L.et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415(6869):2002;331-335.
43. Prevec L., Campbell J.B., Christie B.S., Belbeck L., Graham F.L. A recombinant human adenovirus vaccine against rabies. J. Infect. Dis. 161(1):1990;27-30.
44. Lubeck M.D., Davis A.R., Chengalvala M. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl. Acad. Sci. U.S.A. 86(17):1989;6763-6767.
45. Alexander J., Del Guercio M.F., Fikes J.D.et al. Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Hum. Immunol. 59(12):1998;776-782.
46. Wedemeyer H., Gagneten S., Davis A.et al. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology. 121(5):2001;1158-1166.
47. Huang S., Hendriks W., Althage A.et al. Immune response in mice that lack the interferon-gamma receptor. Science. 259(5102):1993;1742-1745.
48. Franco A., Ferrari C., Sette A., Chisari F.V. Viral mutations, TCR antagonism and escape from the immune response. Curr. Opin. Immunol. 7(4):1995;524-531.
49. Shindo M., Di Bisceglie A.M., Hoofnagle J.H. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology. 15(6):1992;1013-1016.
50. Cerny A., McHutchison J.G., Pasquinelli C.et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 95(2):1995;521-530.
51. Borysiewicz L.K., Hickling J.K., Graham S.et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kDa immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med. 168(3):1988;919-931.
52. Carmichael A., Jin X., Sissons P., Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177(2):1993;249-256.
53. Lauer G.M., Nguyen T.N., Day C.L.et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J. Virol. 76(6):2002;2817-2826.